Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ambrisentan in PAH - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.

NCT00423202 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT00423202
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00423202 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ambrisentan in PAH - A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Efficacy Study of Ambrisentan in Subjects With Pulmonary Arterial Hypertension.
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2003
Completion date
October 31, 2005
Enrollment
186
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension